CDSCO approves antibody cocktail drug for restricted emergency use to treat mild Covid-19 cases
CDSCO approves use of antibodies cocktail drug (Casirivimab and Imdevimab) for restricted emergency use to treat mild to moderate Covid-19 in adults and paediatric patients.
advertisement
Health workers inspect Covid-19 patients at a hospital in New Delhi. (Photo credit: PTI).
The Indian regulatory body, Central Drugs Standards Control Organisation (CDSCO), has approved the use of antibodies cocktail drug (Casirivimab and Imdevimab), for restricted emergency used to treat mild to moderate Covid-19 in adults and paediatric patients (12 years or weighing more than at least 40 kg).
Antibodies Cocktail Drug can be a game-changer in Covid-19 treatment, especially when these are recommended to be given at the early stages of laboratory-confirmed SARS-CoV-2 infection positive result. Theis is preferebly administered within 10 days of symptoms onset.
URL copied
representational image
During COVID 19 second wave in India, a number of people are seen hunting for oxygen cylinders, ICU beds and many more medical facilities across the country. Remdesivir is also one of the drugs many have been searching for their loved ones. So what is Remdesivir? Is this a life saving COVID 19 drug? Should it be given to every coronavirus positive patient? Can Remdesivir be given to COVID patients treated at home? Know all about it here:
According to an infographic video shared by PIB fact check, a verified Twitter account by the government of India to counter misinformation on govt. policies/schemes, Remdesivir is an experimental investigational drug that is granted for emergency authorisation use only. It is advisable for people who are moderately sick and are receiving oxygen. Furthermore, studies do not show mortality reduction with this drug. Moreover, Remdesivir is to be administered in hospitals settings only
This emergency use authorisation (EUA) will now enable Roche to import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla Limited.
Gilead to help boost production of remdesivir in India, promises to donate 4.50 lakh vials
Gilead to help boost production of remdesivir in India, promises to donate 4.50 lakh vials
American biopharmaceutical company Gilead has announced steps to boost remdesivir production in India as the country sees a surge in the Covid-19 cases. It has also announced to donate 4.50 lakh vials to India.
advertisement
Gilead will help boost production of remdesivir in India
American biopharmaceutical company Gilead has announced steps to expand the availability of remdesivir, a key therapeutic medicine used in the treatment of COVID-19 patients, in India.
Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalised with severe disease.
Gilead to help India spur Remdesivir production; promises 45,000 vials
In addition to providing support to its licensees to expand their local manufacturing capacity, Gilead will also donate at least 450,000 vials of Remdesivir to help address the immediate needs of Indian patients
PTI | April 27, 2021 | Updated 09:06 IST
American biopharmaceutical company Gilead has announced steps to expand the availability of remdesivir, a key therapeutic medicine used in the treatment of COVID-19 patients, in India. The recent surge of COVID-19 cases in India is having a devastating impact on communities and has created unprecedented pressure on health systems, Johanna Mercier, chief commercial officer of Gilead Sciences said on Monday.